Clinical Trial Update: TNFα Monoclonal Antibody for Acute Spinal Cord Injury [Phase 1, Phase 2]

View source ↗

Summary

An early-stage clinical trial update for a TNFα monoclonal antibody targeting acute spinal cord injury, spanning Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Cord Injury

Drugs mentioned

• TNFα monoclonal antibody

Snippet

Sponsor: Shanghai Changzheng Hospital | Conditions: Spinal Cord Injuries | Phase 1, Phase 2 | Status: UNKNOWN